Your browser version may not work well with NCBI's Web applications. More information here...
1: Arthritis Res. 2001;3(3):154-7. Epub 2001 Feb 26.Click here to read Click here to read Links

Genetic epidemiology. Giant cell arteritis and polymyalgia rheumatica.

Gonzalez-Gay MA.

Rheumatology Division, Hospital-Xeral Calde, Lugo, Spain. miguelaggay@hotmail.com

Giant cell arteritis (GCA) (temporal arteritis) and polymyalgia rheumatica (PMR) are common, frequently related conditions in people generally over 50 years of age. Most studies have shown an association of GCA with HLA-DRB1 *04 alleles. As regards isolated PMR, however, the HLA class II genetic susceptibility varies from one population to another. Besides associations with HLA, tumor necrosis factor appears to influence susceptibility to both conditions. Genetic polymorphisms have also been considered to be important candidates as factors of susceptibility to GCA and PMR. In this regard, gene polymorphisms for ICAM-1 (intercellular adhesion molecule 1), RANTES (regulated upon activation, normal T cell expressed, and presumably secreted), and interleukin (IL)-1 receptor antagonist seem to play a role in the pathogenesis of GCA and PMR in some populations. However, additional studies are required to clarify the genetic influence on susceptibility to these conditions.

PMID: 11299056 [PubMed - indexed for MEDLINE]

PMCID: PMC128892

Patient Drug Information

  • Anakinra (Kineret® )

    Anakinra is used, alone or in combination with other medications, to reduce the pain and swelling associated with rheumatoid arthritis. Anakinra is in a class of medications called interleukin antagonists. It works by bl...

  • Abatacept (Orencia, Humira, Amevive, ...)

    How do targeted immune modulators compare in treating rheumatoid arthritis?

  • Source: AHFS Consumer Medication Information